EGFR and atherosclerosis: There is evidence that selective deleting or inhibiting EGFR in myeloid cells or CD4+ T cells limits atherosclerosis via reducing inflammatory factors production, such as TNF-α, IL-6, IL-4, IL-2, along with suppressing cytoskeletal rearrangements and also lipid uptake by macrophages and inducing anergy (Zeboudj et al. 2018a, b).